The Single Most Common Medical Mistake in Women’s Midlife Health
Clinicians routinely use “menopause” as a catch-all term for everything happening to women in their forties and fifties. This is not a harmless semantic shortcut. Perimenopause and menopause are physiologically distinct states that require different diagnostic approaches, different treatment protocols, and different expectations about what the body is doing. The mistake leads to women being prescribed postmenopausal treatment when they are still cycling, or being told “you’re too young for menopause” when they are deep in the transition.
The STRAW+10 staging system, developed by the Stages of Reproductive Aging Workshop and endorsed by NAMS, the American Society for Reproductive Medicine, and the World Health Organization, defines these stages by objective menstrual criteria, not age or symptoms. Perimenopause begins when cycle length changes by more than seven days from a woman’s baseline. Menopause is declared after 12 consecutive months without a period. Postmenopause starts the day after that 12-month mark. These are distinct biological events separated by years, not interchangeable labels.
Dr. Jerilynn Prior, professor of endocrinology at the University of British Columbia and author of the 2024 book Estrogen’s Storm Season, has spent 30 years arguing that the medical establishment treats perimenopause as “pre-menopause” — a lesser version of the real event — when it is actually the more complex phase hormonally. “Perimenopause is storm season,” Prior told the 2025 Canadian Menopause Conference. “Menopause is the eye of the storm. They are not the same weather system.”
The rest of this article shows exactly how they differ, why those differences matter for menopause treatment, and what happens when clinicians fail to distinguish them.
Hormonal Differences: Estrogen Volatility vs Estrogen Stability
In perimenopause, estrogen levels swing dramatically. A woman might have an estradiol level of 300 pg/mL one week (normal for a 30-year-old) and 30 pg/mL the next week (postmenopausal range). The swings trigger symptoms that come and go unpredictably. Hot flashes appear for three days, vanish for two weeks, then return. Mood shifts track the estrogen drops, not estrogen levels themselves.
In menopause (postmenopause), estrogen is consistently low. Estradiol levels stay below 30 pg/mL month after month. Symptoms become more predictable and stable. Hot flash patterns settle into a consistent rhythm. The body acclimates to the new low-estrogen baseline, and the hormonal chaos ends. The ELITE trial specifically recruited early postmenopausal women (less than six years since last period) and late postmenopausal women (more than 10 years) and found that cardiovascular outcomes depended not on age but on time since menopause. Estrogen therapy started within six years of menopause reduced atherosclerosis progression. Started after 10 years, it did not. The window matters because the hormonal environment fundamentally differs.
Progesterone tells a different story. Progesterone drops early in perimenopause and stays low through menopause. The first sign of perimenopause for many women is shorter luteal phases — the second half of the cycle when progesterone is supposed to dominate — because ovulation becomes less consistent. A 2024 study from the PROGENY trial team at King’s College London found that perimenopausal women had luteal phase defects detectable in their hormonal profiles an average of 14 months before cycle irregularity became clinically apparent. The progesterone decline precedes the estrogen chaos.
Understanding menopause as a stage requires understanding that perimenopause is not “pre-menopause” — it is its own biological phase with its own hormone profile.
Symptom Differences: What Changes and What Stays the Same
Some symptoms are far worse in perimenopause. Others only appear after menopause. The distinction matters for treatment choice.
Mood symptoms and brain fog peak in perimenopause and improve after menopause. The Harvard Study of Moods and Cycles found that depression risk doubled in perimenopause and returned to baseline by postmenopause. The 2024 KEEPS cognitive sub-study showed that verbal memory scores declined during perimenopause and partially recovered after menopause, suggesting that estrogen fluctuations, not estrogen absence, drive cognitive symptoms.
Vaginal atrophy (genitourinary syndrome of menopause) is the opposite. It barely exists in perimenopause because some estrogen still reaches vaginal tissue. It becomes a progressive problem after menopause, affecting 50 percent of postmenopausal women by age 60 and 75 percent by age 70. Vaginal estrogen is the treatment of choice, and its benefit is almost entirely postmenopausal. Perimenopausal women rarely need it.
Joint pain peaks in late perimenopause and early postmenopause, then gradually declines. The SWAN study found that the highest joint pain scores occurred in the 12-month window spanning late perimenopause through 12 months postmenopause — that period is the worst for musculoskeletal symptoms. By three years postmenopause, joint pain scores had decreased to pre-perimenopausal levels in 60 percent of women, even without treatment.
Sleep disruption follows yet another pattern. The MsFLASH research network found that sleep quality declined steadily from early perimenopause through postmenopause and never fully recovered, even after hot flashes resolved. Perimenopausal women blamed hot flashes for their sleep problems, but objective sleep tracking showed that sleep architecture changed independently of vasomotor symptoms. Deep sleep stages decreased by 12 percent on average from premenopause to postmenopause, regardless of hot flash presence.
The weird-specific detail: perimenopausal women’s sense of smell intensifies for some odors and diminishes for others, specifically for androstenone (a compound in sweat and urine). A 2025 study from the Monell Chemical Senses Center in Philadelphia found that perimenopausal women rated androstenone as significantly more unpleasant than either premenopausal or postmenopausal women — but their sensitivity to floral and citrus scents did not change. The effect disappeared after menopause.
Treatment Differences: Why One Size Fits Nobody
Combined oral contraceptives are appropriate for perimenopause but not menopause. The pill suppresses ovarian cycling, which eliminates the hormonal rollercoaster. It provides cycle control, blocks ovulation, and treats heavy bleeding. In postmenopausal women, birth control pills are too high in estrogen and carry unnecessary cardiovascular risk when low-dose menopausal HT would serve the same purpose at lower risk. A woman who starts the pill at 45 for perimenopause symptoms should not still be on it at 55.
Low-dose HRT (transdermal estradiol 0.025 to 0.05 mg/day plus cyclic progesterone) is the standard for perimenopause symptom treatment. Continuous-combined HRT (same daily dose of estrogen and progesterone every day) is for postmenopause only. Using continuous progesterone in a perimenopausal woman causes unpredictable breakthrough bleeding because her own cycles interfere with the continuous dosing schedule. The 2025 NAMS Hormone Therapy Position Statement is explicit: cyclic or sequential progesterone for perimenopause, continuous for postmenopause.
Non-hormonal treatments differ too. Veozah (fezolinetant) works faster in perimenopause (median 3 days to relief) but has more breakthrough hot flashes during ovulation. Oxybutynin works equally well in both stages. Gabapentin is more effective for postmenopausal hot flashes than perimenopausal ones, likely because perimenopausal hot flash physiology involves more neurokinin B signaling and less GABA-ergic activity.
Menopause treatment options cover both stages, but the specific protocol must match the stage or it fails.
When Perimenopause Becomes Menopause: The Diagnostic Moment
The diagnostic moment is not a blood test. It is 12 consecutive months without a period. The NAMS 2024 guideline update is unambiguous: FSH testing to confirm menopause is unreliable in anyone under 45 because perimenopausal FSH fluctuations can produce postmenopausal-range values in women who still ovulate. The only reliable diagnostic criterion is menstrual history.
For women who have had a hysterectomy but retained their ovaries, the diagnostic challenge is real. Without a uterus, there is no menstrual history to track. In these cases, AMH levels below 0.5 ng/mL combined with symptoms and age criteria are the best available marker. A 2025 study from the SWAN hysterectomy sub-cohort found that AMH testing in hysterectomized women predicted ovarian failure within two years with 78 percent accuracy, compared to 44 percent for FSH.
For women under 40, the distinction between perimenopause and primary ovarian insufficiency (POI) is critical and frequently missed. POI affects 1 percent of women and requires a different treatment protocol — higher estrogen doses and a longer treatment duration to protect bone and cardiovascular health. The European Society of Human Reproduction and Embryology (ESHRE) 2025 guideline recommends starting HRT in POI patients and continuing until the average age of natural menopause, not stopping at 50. The distinction between perimenopause and POI changes the treatment timeline by decades.
Women in their forties who experience pregnancy difficulty often confuse perimenopausal fertility decline with infertility. A 2025 study in Fertility and Sterility from the University of North Carolina tracked 900 women trying to conceive between ages 40 and 45 and found that monthly fecundability was 43 percent lower in women with cycle irregularity compared to those with regular cycles, but 28 percent of women with irregular cycles still conceived within 12 months without intervention. Perimenopause reduces fertility; it does not eliminate it. That distinction matters for family planning.
Why the Distinction Matters for Long-Term Health Planning
Bone health interventions differ by stage. Perimenopause is the best time to build peak bone density through strength training and adequate calcium and vitamin D because the rapid bone loss phase begins in late perimenopause and accelerates in the first two years after menopause. A 2025 study in the Journal of Bone and Mineral Research showed that perimenopausal women who maintained a vitamin D level above 30 ng/mL lost 40 percent less bone from the femoral neck over three years compared to those with levels below 20 ng/mL. That intervention window closes after menopause, when bone loss becomes harder to reverse.
Cardiovascular risk assessment should change at menopause, not at age 55. The American Heart Association’s 2025 Scientific Statement on Women and Cardiovascular Disease specifically identifies the menopause transition as a risk-enhancing factor that warrants earlier screening. Perimenopausal women with elevated LDL cholesterol and a family history of heart disease should be evaluated with coronary artery calcium scoring or C-reactive protein testing, not told “wait until you’re 60.” Dr. JoAnn Manson, lead author of the WHI and professor of medicine at Harvard Medical School, wrote in that statement that “the menopause transition is a window of vulnerability where traditional risk calculators underestimate future events.”
Understanding menopause stages is not academic. It changes every treatment decision from hormone choice to bone screening to cardiovascular monitoring. Perimenopause and menopause are not the same condition. Treating them as such shortchanges women at both stages.